

REVIEW ARTICLE

# A scoping review establishes need for consensus guidance on reporting health equity in observational studies

Xiaoqin Wang<sup>a</sup>, Omar Dewidar<sup>b</sup>, Anita Rizvi<sup>c</sup>, Jimmy Huang<sup>b</sup>, Payaam Desai<sup>b</sup>, Rebecca Doyle<sup>b</sup>, Elizabeth Ghogomu<sup>b</sup>, Tamara Rader<sup>d</sup>, Stuart G. Nicholls<sup>e</sup>, Alba Antequera<sup>f</sup>, Alison Krentel<sup>b,g</sup>, Beverley Shea<sup>b,g</sup>, Billie-Jo Hardy<sup>h,i</sup>, Catherine Chamberlain<sup>j</sup>, Charles S. Wiysonge<sup>k,l,m</sup>, Cindy Feng<sup>n</sup>, Clara Juando-Prats<sup>h,i</sup>, Daeria O. Lawson<sup>o</sup>, Ekwaro A. Obuku<sup>p,q,r</sup>, Elizabeth Kristjansson<sup>c</sup>, Erik von Elm<sup>s</sup>, Harry Wang<sup>b,t</sup>, Holly Ellingwood<sup>u</sup>, Hugh Sharma Waddington<sup>v,w</sup>, Jacqueline Ramke<sup>x,y</sup>, Janet Elizabeth Jull<sup>z</sup>, Janet Hatcher-Roberts<sup>b,g</sup>, Janice Tufte<sup>aa</sup>, Julian Little<sup>g</sup>, Lawrence Mbuagbaw<sup>ab,ac,ad,ae,af</sup>, Laura Weeks<sup>ag</sup>, Loveline Lum Niba<sup>ah</sup>, Luis Gabriel Cuervo<sup>ai</sup>, Luke Wolfenden<sup>aj</sup>, Mwenya Kasonde<sup>ak</sup>, Marc T. Avey<sup>al</sup>, Melissa K. Sharp<sup>am</sup>, Michael Johnson Mahande<sup>an</sup>, Miriam Nkangu<sup>g</sup>, Olivia Magwood<sup>b,ao</sup>, Peter Craig<sup>ap</sup>, Peter Tugwell<sup>b,g,aq</sup>, Sarah Funnell<sup>ar,as</sup>, Stephen G. Noorduyn<sup>o</sup>, Tamara Kredon<sup>l</sup>, Tanya Horsley<sup>at</sup>, Taryn Young<sup>k</sup>, Tomas Pantoja<sup>au</sup>, Zulfiqar Bhutta<sup>av,aw</sup>, Andrea Martel<sup>ax</sup>, Vivian A. Welch<sup>b,g,\*</sup>

<sup>a</sup>Michael G. DeGroot Institute for Pain Research and Care, McMaster University, Hamilton, Ontario L8S 4L8, Canada

<sup>b</sup>Bruyère Research Institute, Ottawa, Ontario K1R 6M1, Canada

<sup>c</sup>School of Psychology, University of Ottawa, Faculty of Social Sciences, Ottawa, Ontario K1N 6N5, Canada

<sup>d</sup>Freelance Health Research Librarian, Ottawa, Canada

<sup>e</sup>Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario K1H 8L6, Canada

<sup>f</sup>International Health Department, ISGlobal, Hospital Clínic - Universitat de Barcelona, 585, 08007 Barcelona, Spain

<sup>g</sup>School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario K1N 6N5, Canada

<sup>h</sup>Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario M5S, Canada

<sup>i</sup>Li Ka Shing Knowledge Institute, Unity Health Toronto, Toronto, Ontario M5B 1T8, Canada

<sup>j</sup>Indigenous Health Equity Unit, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, 3010 Victoria, Australia

<sup>k</sup>Centre for Evidence-based Health Care, Department of Global Health, Stellenbosch University, Cape Town 7505, South Africa

<sup>l</sup>Cochrane South Africa, South African Medical Research Council, Cape Town, 3629, South Africa

<sup>m</sup>HIV and other Infectious Diseases Research Unit, South African Medical Research Council, Durban 4091, South Africa

<sup>n</sup>Department of Community Health and Epidemiology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia B3H 4R2, Canada

<sup>o</sup>Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario L8S 4L8, Canada

<sup>p</sup>Africa Centre for Systematic Reviews & Knowledge Translation, College of Health Sciences, Makerere University, Kampala 7062, Uganda

<sup>q</sup>Department of Global Health Security, Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala 7062, Uganda

<sup>r</sup>Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, University of London, London WC1E 6BT, United Kingdom

<sup>s</sup>Cochrane Switzerland, Unisanté Lausanne, Lausanne, CH 1010, Switzerland

<sup>t</sup>University of Ottawa Faculty of Medicine, Ottawa, Ontario K1N 6N5, Canada

<sup>u</sup>Department of Psychology, Department of Law, Carleton University, Ottawa, Ontario K1S 5B6, Canada

<sup>v</sup>Environmental Health Group, Department of Disease Control, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK

<sup>w</sup>London International Development Centre, London, Ontario N5V 4T3, Canada

<sup>x</sup>International Centre for Eye Health, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK

<sup>y</sup>School of Optometry and Vision Science, University of Auckland, Auckland 1010, New Zealand

<sup>z</sup>School of Rehabilitation Therapy, Queen's University, Kingston, Ontario K7L 3N6, Canada

<sup>aa</sup>Cochrane Consumer, Seattle, WA, USA

<sup>ab</sup>Department of Anesthesia, McMaster University, Hamilton, Ontario L8S 4L8, Canada

<sup>ac</sup>Department of Pediatrics, McMaster University, Hamilton, Ontario L8S 4L8, Canada

Funding sources: This work was supported by the Canadian Institutes of Health Research (CIHR), grant number 173269. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

\* Corresponding author. School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario K1N 6N5, Canada. Tel: +1-613-219-9290.

E-mail address: [vivian.welch@uottawa.ca](mailto:vivian.welch@uottawa.ca) (V.A. Welch).

- <sup>ad</sup>Biostatistics Unit, Father Sean O’Sullivan Research Centre, St Joseph’s Healthcare, Hamilton, Ontario L8N 4A6, Canada
- <sup>ae</sup>Centre for Development of Best Practices in Health (CDBPH), Yaoundé Central Hospital, VGC6+C52, Yaoundé, Cameroon
- <sup>af</sup>Division of Epidemiology and Biostatistics, Department of Global Health, Stellenbosch University, Cape Town 7602, South Africa
- <sup>ag</sup>CADTH, Ottawa, Ontario K1S 5S8, Canada
- <sup>ah</sup>Department of Public Health, Faculty of Health Sciences, The University of Bamenda, Amphi 340, Bamibli, Bamenda, Cameroon
- <sup>ai</sup>Pan American Health Organization (PAHO/WHO), Washington, DC 20037, USA
- <sup>aj</sup>School of medicine and Public Health, The University of Newcastle, Callaghan, NSW 2308, Australia
- <sup>ak</sup>Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK
- <sup>al</sup>Canadian Council on Animal Care, Ottawa, Ontario K2P 2R3, Canada
- <sup>am</sup>Department of General Practice, RCSI University of Medicine and Health Sciences, Dublin D02 YN77, Ireland
- <sup>an</sup>Department of Epidemiology & Biostatistics, Kilimanjaro Christian Medical University College, Kilimanjaro M8HH+MQ4, Tanzania
- <sup>ao</sup>Interdisciplinary School of Health Sciences, University of Ottawa, Ottawa, Ontario K1N 6N5, Canada
- <sup>ap</sup>MRC/CSO Social and Public Health Science Unit, University of Glasgow, Glasgow G12 8QQ, UK
- <sup>aq</sup>Department of Medicine, University of Ottawa, Ottawa, Ontario K1N 6N5, Canada
- <sup>ar</sup>Department of Family Medicine, Queen’s University, Kingston, Ontario K7L 3N6, Canada
- <sup>as</sup>Department of Family Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario K1N 6N5, Canada
- <sup>at</sup>Royal College of Physicians and Surgeons of Canada, Ottawa, Ontario K1S 5N8, Canada
- <sup>au</sup>Department of Family Medicine, Pontificia Universidad Católica de Chile, Santiago 8331150, Chile
- <sup>av</sup>Centre for Global Child Health, The Hospital for Sick Children, Toronto, Ontario M5G 1X8, Canada
- <sup>aw</sup>Institute for Global Health and Development, The Aga Khan University, Karachi 74000, Pakistan
- <sup>ax</sup>Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario M5S, Canada

Accepted 9 June 2023; Published online 15 June 2023

## Abstract

**Objectives:** To evaluate the support from the available guidance on reporting of health equity in research for our candidate items and to identify additional items for the Strengthening Reporting of Observational studies in Epidemiology–Equity extension.

**Study Design and Setting:** We conducted a scoping review by searching Embase, MEDLINE, CINAHL, Cochrane Methodology Register, LILACS, and Caribbean Center on Health Sciences Information up to January 2022. We also searched reference lists and gray literature for additional resources. We included guidance and assessments (hereafter termed “resources”) related to conduct and/or reporting for any type of health research with or about people experiencing health inequity.

**Results:** We included 34 resources, which supported one or more candidate items or contributed to new items about health equity reporting in observational research. Each candidate item was supported by a median of six (range: 1–15) resources. In addition, 12 resources suggested 13 new items, such as “report the background of investigators”.

**Conclusion:** Existing resources for reporting health equity in observational studies aligned with our interim checklist of candidate items. We also identified additional items that will be considered in the development of a consensus-based and evidence-based guideline for reporting health equity in observational studies. © 2023 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

**Keywords:** Health equity; Observational studies; Reporting guideline; Scoping review; STROBE\_Equity; Reporting item

## 1. Introduction

Health inequities are defined as “differences which are unnecessary and avoidable, unfair and unjust” [1]. Health inequities exist across numerous dimensions such as income, education, geographical setting, age, ethnicity, and gender; these factors are well documented in influencing health outcomes [2–4]. These health disparities have persisted despite global efforts to reduce them by organizations such as the World Health Organization (WHO) and United Nations International Children’s Emergency Fund [5–8]. Addressing the health needs of populations experiencing inequities requires conducting research merging scientific standards and their sociocultural contexts.

Observational studies predominate in health-related research [9] and are well suited to answer research questions of health inequity such as access, implementation,

treatment adherence, and public health interventions [10–12]. We defined observational studies as those relevant to the Strengthening Reporting of Observational studies in Epidemiology (STROBE) reporting guideline, including case-control, cohort, and cross-sectional studies [13]. Compared with some randomized controlled trials (RCTs), observational studies have inherently stronger external validity because they provide an insight about healthcare delivery to all patients in routine practice, the health impacts of policy and practice interventions, and of potentially harmful exposures, including among those populations at risk of disadvantage due to inequities [14,15]. Evidence suggests that strong observational studies such as discontinuity designs produce estimates which are statistically identical to RCTs [16]. During the COVID-19 pandemic, observational studies highlighted the inequities in the direct and indirect consequences of SARS-CoV-2

### What is new?

#### Key findings

- All candidate items proposed to extend Strengthening Reporting of Observational studies in Epidemiology for equity were supported by at least one resource.
- We identified 13 additional items related to defining health equity terms; these described the role of racism and discrimination, composition and training of the researcher(s), considering relevant factors in the study methods, and data sharing specific to and across equity factors.

#### What this adds to what was known?

- Through the current resources, we confirmed the support of the interim checklist of items and identified new items for reporting health equity in observational studies. This adds an important tool for observational studies, including those underpinning public health, and health systems and services research.

#### What is the implication and what should change now?

- Researchers designing observational studies could refer to the items from this review when designing and reporting their studies.
- These items will be used for the consensus process to develop a research reporting guideline on health equity to extend Strengthening Reporting of Observational studies in Epidemiology.

infection and attempts to control it [17–19], thus playing a critical role in informing public health responses [20–22]. In addition, in cases where conducting an RCT would be unethical, observational studies become the most reliable source of evidence [23].

Despite the predominance of observational studies in health research, many such studies do not adequately report information such as clear eligibility criteria, reliability and validity of measurements, and details on data gaps [24–28]. The reporting guideline for observational studies (STROBE) [15] released in 2007 has been widely used by journals and authors of observational research [29] and has been cited 29,276 times according to Google Scholar as of November 28, 2022 [30]. Nonetheless, the reporting of intervention effects across health equity determinants in observational studies is far from ideal. For example, researchers consistently found a lack of integration and reporting of sex and gender in observational studies [31–33]. This gap may be partly because STROBE lacks

items tailored for health equity, for example, in describing equity seeking populations, evaluating outcomes across PROGRESS (i.e., place of residence, race/ethnicity/culture/language, gender/sex, religion, education, socioeconomic status, social capital) factors, and appraising applicability. As such, it is necessary to develop, endorse, and implement reporting guidelines to improve the reporting of health equity in observational studies [34–36].

In response to this gap, we established a global, multi-disciplinary team that includes academics, policymakers, participants with lived experience, practitioners, advisors, and regular peer reviewers to journals, funders, and other knowledge users [37] across a range of disciplines including Indigenous health, knowledge translation, equity, social science, epidemiology, biostatistics, and other health sciences. We aim to develop the STROBE\_Equity extension to encourage transparent, concise, and comprehensive reporting of health equity in observational studies [38]. As described in a previous study [17], the team formulated an interim checklist of 36 candidate items by reviewing existing checklists related to equity such as the Consolidated Standards of Reporting Trials (CONSORT)—Equity, the Sex and Gender Equity in Research reporting guidelines and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)—Equity, and convened a citizen panel (H.E., J.T., and R.G.) with lived experience of health inequities to seek their feedback. The interim checklist could be found in the [Supplemental Table B1](#) [17].

This scoping review aims to describe the extent to which the available guidance on reporting of health equity in research supports our candidate items (interim guidance) and to identify new items that could be used for the STROBE-Equity extension guideline.

## 2. Methods and analysis

### 2.1. Protocol and registration

We set up a governance structure of an executive team of four principal investigators (V.W., L.M., J.J., and S.F.) and a lead for each of three steering committees (Indigenous, Knowledge user, and Patient/Public) and a Technical Oversight committee to ensure all the team members participated in an integrated knowledge translation process to develop the protocol of this review. The steering committees and Technical Oversight committee are consulted for input on design and delivery of all the relevant studies under the STROBE\_equity project and for feedback on the research results. The executive team meets monthly with a research coordinator and leaders of the studies to consult on study methods and issues arising during the conduct. The executive team, the Technical Oversight Committee, and the steering committees meet quarterly by video conference for project updating and consultation as needed [39]. Following the Joanna Briggs Institute (JBI) method

[40], we conducted this study in adherence with a peer-reviewed protocol published in BMJ Open [41] and reported according to the PRISMA reporting guideline for Scoping Reviews [42].

## 2.2. Eligibility criteria

We included the following types of resources: (1) guidance related to conduct or reporting for any type of research on, with, or about people experiencing health inequity; (2) methodology reviews assessing reporting of equity-related issues of research; (3) summary reports of recommendations on reporting for equity issues in research; and (4) relevant guidance from ethics boards, funders, and journal policies on the conduct or reporting of research related to health equity. We excluded resources without recommendation (a statement explaining why specific information is important or recommending reporting specific information in research of health) related to health equity reporting. There was no restriction on language of the publication. As described in the protocol, we decided to conduct two scoping reviews (one for Indigenous and one for ‘global’ stream) based on the available data and consultation with Indigenous researchers [39,41]. Here, we only included resources that considered nonindigenous populations; resources tailored for research with Indigenous Peoples were designated to the scoping review led by Miranda Lesperance, Sarah Funnell, and Andrea Martel to avoid double use. The results of the two scoping reviews will be used together to inform the global and Indigenous STROBE-equity reporting guideline [39]. Indigenous Peoples were defined as “... distinct social and cultural groups that share collective ancestral ties to the lands and natural resources where they live, occupy, or from which they have been displaced.” [43].

Although there are unique aspects on reporting health equity information in observational studies, we did not restrict the focus to observational studies because guidance for other types of studies, such as RCTs, could also provide important and relevant information that is shared by observational studies. For example, although the CONSORT equity reporting guideline is focused on RCTs, it has some items that are relevant for observational studies [17,36].

## 2.3. Search strategy

We searched for both peer-reviewed and nonpeer-reviewed published guidance on the reporting and conduct of health equity-related research. The search was conducted in MEDLINE via OVID, LILACS via BIREME–PAHO–WHO Latin American and Caribbean Center on Health Sciences Information (<http://lilacs.bvsalud.org/en/>), the Cochrane Methodology Register (Wiley), Embase via OVID, and CINAHL via EbscoHost in January 2022. A full search strategy was developed in MEDLINE using the following concepts: (1) health equity (using PROGRESS-

Plus [44] characteristics); (2) reporting, analysis, and design of research; and (3) guidelines or guidance articles. We assessed relevance of the search results through testing with a set of 11 target articles and modified the search until all these were identified. Searches were limited to records published in 2005 and later considering that (1) we are interested in recent guidance and conceptualizations of health equity in research and (2) the establishment of the Commission on Social Determinants of Health by the WHO was in 2005. No language limit or study design limit was applied. Search strategies are presented in [Supplementary Table B2](#). Searches were designed and conducted by a librarian (T.R.) experienced in systematic reviews, using a method designed to optimize term selection [45]. After identifying eligible full texts from databases, we checked the reference lists for additional eligible studies or documents.

We classified gray literature into five categories and searched for guidance within each: journal guidance from Journal Citation Reports [46], publisher policies from the Joint commitment for action [47], ethics guidance from the International Compilation of Human Research Standards [48], generic research guidance from funding agencies [49], and reporting guidance from interest groups across PROGRESS-Plus factors in consultation with the technical committees. We sampled randomly from these five categories in intervals of 20 documents at a time, stratified by country income setting (i.e., high-income countries, middle-income countries, and low-income countries) as defined by the World Bank to get more representative information from the entire research world (<https://data.worldbank.org/country/XD>). We decided the information as saturation if no new recommendation was found per category of the gray literature, and we stopped searching further in this case. Detailed methods and results of gray literature are presented in [Supplementary Table B3](#).

## 2.4. Study selection process

Search results from databases were imported into Covidence (<https://www.covidence.org/>). Pairs of reviewers (P.D., J.H., R.D., O.D., A.R.) screened titles and abstracts and full texts in duplicate and independently. All disagreements were resolved through team discussions.

## 2.5. Data items and extraction

In this scoping review, we developed the data extraction form based on the interim STROBE\_Equity guidance and the 36 candidate items [17] using Microsoft Excel 2022 (Version 16.58). We tested the form three times with 2–3 included resources each time and modified as required based on feedback from the team. We considered the different publication types and scope of the studies (e.g., we tested our form with reports of different study designs).

After three rounds of pilot-testing, we started the formal data abstraction.

Pairs of reviewers (X.W., J.H., P.D., R.D., O.D., E.G.) extracted data for each included study independently and discussed for consensus. A third reviewer (V.W.) was consulted for a final decision where necessary. All extractions were verified as an additional data cleaning step (X.W.). We collected characteristics on the source, type of organization, scope of the document (e.g., population, setting, and type of study design), and methods of development. The extraction form can be found in [Supplementary Appendix A](#).

For judgments on whether or not the guidance supports the preliminary STROBE\_Equity extension items, we selected from options “support (i.e., suggest reporting)” or “nothing relevant”. We also collected the supporting verbatim text and captured any potential new items as free text with verbatim quotes from the source document.

### 2.6. Methodological quality appraisal

Consistent with the JBI guidance on scoping review conduct, we did not appraise methodological quality or risk of bias of the included studies [50].

### 2.7. Data analysis and presentation of the evidence

We used the principles of framework synthesis to analyze the data [51]. First, we mapped the recommendations to the preliminary STROBE\_Equity checklist of 36 candidate items as our a priori framework. Online meetings among team members (X.W., O.D., E.G., V.W., R.D., J.H., P.D.) were held to evaluate the support for each item of the interim checklist and identify any new items. For recommendations that did not match the items in the checklist, we applied an inductive thematic analysis to develop new items or categories as needed [52]. We also assessed the new items for overlapping concepts and then combined and drafted wording based on the existing guidance. The wording of the candidate items was then clarified as necessary and finalized with the writing team and the wider STROBE\_Equity team.

Data synthesis included (1) descriptive quantitative analysis (frequencies and proportions) of the characteristics for included resources and the supporting recommendations for the preliminary STROBE\_Equity checklist of candidate items and (2) qualitative analysis (i.e., content analysis) of supporting recommendations for each candidate or new item.

We presented the results as a map of the extracted data in tabular form based on the a priori framework according to the STROBE structure (e.g., introduction, methods, results, discussion). The unit used when counting the number of sources was the study; thus, if a study was published in more than one report, the reports associated with the study were collectively counted as a single source. For example, the GRADE equity guidelines were published as a series of

four reports: the first provided a preamble and rationale and the other three focused on guidance for health guideline developers [53–56].

## 3. Results

### 3.1. Literature search


The electronic database literature search resulted in 12,539 records ([Figure 1](#)). We retained 153 relevant full-text papers after title and abstract screening. After reviewing the full texts, we found 20 eligible studies from academic databases. In addition, we identified seven eligible citations through screening reference lists of included studies and seven eligible resources from the first set of 21 gray literature. In total, we included 34 eligible resources supporting at least one candidate item or suggested a new item ([Supplementary Table B4](#)). [Supplementary Table B5](#) presented the 33 excluded reports that met all the other criteria but did not make recommendations related to reporting health equity.

### 3.2. Characteristics of included resources that informed any candidate item or new item

Of the 34 included resources, most of those informing candidate items were journal articles ( $n = 24$ , 71%). Other resources included documents or webpages from research ethics guidance, government, journal editor, and nongovernmental organizations. The types of resources included varied but were primarily methodology guidelines (11, 32%), reporting guidelines (seven, 21%), and research ethics guidance (seven, 21%). Of the 17 methodology and reporting guidelines, only five (15%) were developed through consensus. All the resources were published in English and 19 (55%) were published since 2015.

### 3.3. Scope of resources that informed any candidate items or new items

Of the 34 resources, nine (26%) focused on specific populations who may experience health inequity, including transgender individuals [61–63], those in remote/rural/underserved/low-socioeconomic settings [64–67], women and minorities [68], and women aged 45–55 years [69]; 25 (74%) were focused on health equity with no population restriction. Most (27; 79%) of the resources were nonspecific to a certain clinical or public health area, whereas seven (21%) focused on specific clinical or public health areas, including oral health [70], psychiatry [71], COVID-19 [72], anesthesia [73], orthopedics [74], preventative medicine [75] and gynecology [69]. Half of the resources had no restriction on PROGRESS-Plus factors; another half focused on one or more specific PROGRESS-Plus factors, where nine (26%) focused on gender or sex [62,63,68,69,73,74,76–78], six (18%) on race/ethnicity/



**Fig. 1.** Preferred reporting items for systematic reviews and meta-analyses (PRISMA) flow diagram \* “Wrong study type” was applied to any report that did not provide guidance on reporting equity in research (e.g., clinical practice guideline) \*\* One was the interim guidelines for reporting health equity in observational studies [17], which was part of this STROBE\_Equity project; Four studies [57–60] about Indigenous Peoples were separated out for the parallel scoping review led by the Indigenous steering committee.

culture/language [68–71,79,80], four (12%) on place of residence [64,65,66,67], and one (3%) on personal, time-dependent, or relationship-dependent factors (i.e., menopausal symptoms among women) [69] (Table 1).

For documents targeting specific study designs, seven (21%) were for all types of primary research, four (12%) for any type of evidence synthesis, four (12%) for clinical trials, and two (6%) for observational studies (Table 1). There were two resources focused on observational studies. One included consolidated criteria for reporting qualitative research including interviews and focus groups [81] and the other was the guidelines for strengthening the reporting of menopause and aging in a cross-cultural comparisons study [69].

### 3.4. Supporting recommendations

For the 34 resources informing any candidate item, each resource supported a median of five candidate items (range 1–22). For the 36 candidate items, the median number of resources supporting an item were six (range 1–15); all candidate items were supported by at least one resource. Six candidate items (one for rationale, four for methods, and

one for results) were informed by more than 10 resources and 21 were informed by more than five resources (Table 2 and Supplementary Table B6). Of the candidate items, rationale for focus on health equity in *Background* (15, 44%), involvement of patients or community experiencing health in equity in *Study design* (13, 38%), sampling/recruitment methods designed to reach populations across PROGRESS-Plus characteristics in *Setting* (16, 47%), and details of informed consent and ethical clearance (13, 38%) were the top four items suggested.

In addition, 11 resources suggested 13 new items (Table 2 and Supplementary Table B7). These items included one for *Title* and suggested using a health equity term; two for *Background* on defining health equity terms and describing the role of racism and discrimination; seven applicable to *Methods*, including topics on reporting the health-equity logic model, composition and training of the researchers considering equity-related factors, reaching people experiencing health inequity, communicating on discontinuation, and describing comparator and technique validation across equity factors; two for *Discussion* on reporting limitations and implications related to health

equity; and one for *Data sharing* on reporting the access to raw data across equity.

#### 4. Discussion

We performed a scoping review of available research guidance and relevant documents across dimensions of health equity from a diverse and comprehensive range of resources to evaluate support for proposed items for a STROBE\_Equity extension.

Our findings show that existing resources for reporting equity in health research are spread across various document types and formats that may be challenging for authors to access and implement in practice. This review provides a contemporary collation of health equity reporting guidance established from a comprehensive review of literature and serves as an important resource for the field.

All candidate items were supported by at least one resource with more than half being supported by more than five resources, suggesting a good alignment of our proposed framework with the current health research landscape. Of these candidate items, rationale for focus on health equity in *Background*, involvement of patients or community experiencing health inequity in *Study design*, sampling/recruitment methods designed to reach populations across PROGRESS-Plus characteristics in *Setting*, and details of informed consent and ethical clearance were the top four items suggested in the resources we included. Additionally, the 13 new items provided more important information on novel intersections, such as describing the role of racism and discrimination in the experience of health inequity in relation to the problem or intervention, reporting the background and research area of the team members considering relevant experience, and providing information on accessing raw data across equity factors. With all these items suggested, our review provides a comprehensive, evidence-based set of reporting items covering all dimensions of reporting health equity in observational studies, including title, abstract, background, methods, result, discussion, and other information (e.g., data sharing).

We identified two resources designed for observational studies, one for qualitative research including interviews and focus groups [81] and the other for guidelines for strengthening the reporting of menopause and aging in a cross-cultural comparisons study [69]. Neither of these covers the breadth of reporting of health equity in observational studies from design to interpretation. Furthermore, we did not identify any reporting guidance that covers all important aspects of reporting health equity—related information in observational studies. Instead, the research guidance related to health equity was fragmented—existing resources for reporting equity in research are spread across various document types and formats that may be challenging for authors to access and implement in practice.

**Table 1.** General characteristics of included resources that informed any reporting items ( $N = 34$ )

Document publisher	N (%)
Academic journal	24 (71)
Research ethics guidance	5 (15)
Government	3 (9)
Journal editor	1 (3)
Nongovernmental organization	1 (3)
Document type	
Methodology guidelines	11 (32)
Reporting guidelines	7 (21)
Research ethics guidance	7 (21)
Methodology review	5 (15)
Editorial/commentary	3 (9)
Journal instruction	1 (3)
Publication year	
2005–2009	6 (18)
2010–2014	9 (26)
2015–2019	10 (29)
2020–2022	9 (26)
Demographic focus	
General population	25 (74)
Focused on specific population <sup>a</sup>	9 (26)
Clinical area focus	
Nonspecific	27 (79)
Specific <sup>b</sup>	7 (21)
PROGRESS-Plus <sup>c</sup>	
Gender or Sex	9 (26)
Race/ethnicity/culture/language	6 (18)
Place of residence	4 (12)
Plus: Personal, time-dependent or relationship dependent factors, such as pregnancy, reproductive capacity	1 (3)
Broad focus <sup>d</sup>	17 (50)
What study design is this document for	
No statement on scope of study design	16 (47)
Any type of primary research	7 (21)
Clinical trials	4 (12)
Any type of evidence synthesis (e.g., systematic review, scoping review)	4 (12)
Observational studies	2 (6)
Clinical practice guidelines	1 (3)

<sup>a</sup> Including transgender health, underserved population, women aged 45–55 years, people who live in rural and remote area, and resource poor setting.

<sup>b</sup> Including oral health, COVID-19, psychiatric anesthesia, women's health, orthopedics, and preventative medicine.

<sup>c</sup> Each document could cover more than one factor.

<sup>d</sup> Broad focus means that the focus is on health equity, but not about specific PROGRESS-Plus factor (e.g., CONSORT-Equity).

Such findings underscore the need for comprehensive reporting resource drawing on such guidance.

Including equity reporting guidance for other study designs gave us a broad view of potential important items.

**Table 2.** Number of sources identified supporting each of the 36 candidate items and 13 new items

Topic	STROBE checklist	Proposed item for an equity-focused extension in observational studies	N (%) of resources
Title and abstract			
Title	1a. Indicate the study's design with a commonly used term in the title or the abstract	<ul style="list-style-type: none"> <li>If health equity is a major focus, consider using "health equity" or relevant terms in the title.<sup>b,c</sup></li> </ul>	2 (6)
Abstract	1b. Provide in the abstract an informative and balanced summary of what was done and what was found	<ul style="list-style-type: none"> <li>Describe population according to PROGRESS-Plus</li> </ul>	8 (24)
		<ul style="list-style-type: none"> <li>Describe extent/limits of applicability to populations of interest across PROGRESS-Plus characteristics</li> </ul>	6 (18)
Background/ rationale			
	2. Explain the scientific background and rationale for the investigation being reported	<ul style="list-style-type: none"> <li>If equity is a focus, what is the rationale for focus on health equity?<sup>c</sup></li> <li>Describing role of racism, discrimination, and exclusion in health inequities across one or more PROGRESS-plus factors in relationship to the research questions.<sup>b,c</sup></li> </ul>	15 (44)
	None	<ul style="list-style-type: none"> <li>Report the definitions of health equity-related terms.<sup>b,c</sup></li> </ul>	1 (3)
Objectives	3. State specific objectives, including any prespecified hypotheses	-	1 (3)
Method			
Study design	4 Present key elements of study design early in the paper	<ul style="list-style-type: none"> <li>Report who was involved/engaged/consulted with experience in health equity/inequity in study design (e.g., patients, community, industry, government, etc.)<sup>c</sup></li> </ul>	13 (38)
		<ul style="list-style-type: none"> <li>Report the background and research area (e.g., personnel with unique professional and cultural backgrounds on equity related issue) and social location (i.e., gender, race, etc.) of investigators.<sup>b</sup></li> </ul>	4 (12)
		<ul style="list-style-type: none"> <li>If applicable, describe whether research staff were selected for or trained with particular skills and experience on working with groups experiencing health inequity (e.g., age inclusion training, disability inclusion training)<sup>b,c</sup></li> </ul>	2 (6)
		<ul style="list-style-type: none"> <li>Report whether a theory of change related to equity was described for the study to design analysis<sup>c</sup></li> </ul>	1 (3)
		<ul style="list-style-type: none"> <li>If applicable, provide the information or link to the logic model developed, which shows how equity is important.<sup>b,c</sup></li> </ul>	1 (3)
		<ul style="list-style-type: none"> <li>Report whether methods of sampling/recruitment were designed to reach populations across relevant PROGRESS-Plus characteristics</li> </ul>	16 (47)
		<ul style="list-style-type: none"> <li>Is there possibility of self-selection bias across PROGRESS-Plus factors?</li> </ul>	2 (6)
Setting	5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	<ul style="list-style-type: none"> <li>If applicable, describe any process in place to monitor and ensure that the research is reaching the people experiencing health inequity appropriately.<sup>b,c</sup></li> </ul>	1 (3)
		<ul style="list-style-type: none"> <li>If applicable, describe how pauses or discontinuation across equity factors were</li> </ul>	1 (3)

(Continued)



Table 2. Continued

Topic	STROBE checklist	Proposed item for an equity-focused extension in observational studies	N (%) of resources
		managed as well as how to communicate with participants. <sup>b,c</sup>	
Participants	6a. Cohort study—Give the eligibility criteria and the sources and methods of selection of participants. Describe methods of follow-up	<ul style="list-style-type: none"> <li>Give inclusion and exclusion criteria across relevant PROGRESS-Plus characteristics</li> </ul>	9 (26)
	Case-control study—Give the eligibility criteria and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	<ul style="list-style-type: none"> <li>Report context and relationship to health equity.<sup>c</sup></li> </ul>	8 (24)
	Cross-sectional study—Give the eligibility criteria and the sources and methods of selection of participants	<ul style="list-style-type: none"> <li>Report details of partnerships with populations and communities, where applicable.<sup>c</sup></li> </ul>	11 (32)
	6b. Cohort study—For matched studies, give matching criteria and number of exposed and unexposed	<ul style="list-style-type: none"> <li>Report whether any PROGRESS-Plus factors used for matching, how categories were determined and why</li> </ul>	1 (3)
	Case-control study—For matched studies, give matching criteria and the number of controls per case		
	None	<ul style="list-style-type: none"> <li>If applicable, describe whether the comparator is considered more advantaged or to have less barriers to health opportunities.<sup>b,c</sup></li> </ul>	1 (3)
Variable	7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	<ul style="list-style-type: none"> <li>Report whether outcomes were identified as relevant and important to populations across PROGRESS-Plus</li> </ul>	10 (29)
		<ul style="list-style-type: none"> <li>If applicable, report whether to measure inequity as an outcome.<sup>c</sup></li> </ul>	4 (12)
Data sources/ measurement	8. <sup>a</sup> For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	<ul style="list-style-type: none"> <li>Report the method of obtaining population characteristics (e.g., age)</li> </ul>	7 (21)
		<ul style="list-style-type: none"> <li>If applicable, describe whether the techniques, especially those developed as diagnostic or quality of life measures were validated or operated similarly across participants regardless of patients' background (e.g., ethnic/linguistic).<sup>b,c</sup></li> </ul>	1 (3)
Bias	9. Describe any efforts to address potential sources of bias	<ul style="list-style-type: none"> <li>Report efforts to reduce selection bias across PROGRESS-Plus</li> </ul>	6 (18)
		<ul style="list-style-type: none"> <li>Report whether dimensions of context might influence the study (e.g., bias in response/participation)</li> </ul>	5 (15)
Study size	10. Explain how the study size was arrived at.	<ul style="list-style-type: none"> <li>Report whether PROGRESS-Plus characteristics of interest were considered in determining the study size</li> </ul>	7 (21)
Quantitative variables	11. Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	<ul style="list-style-type: none"> <li>Report how decisions were made about analyses related to PROGRESS-Plus, including whether any categories were defined, and how they were decided</li> </ul>	9 (26)
		<ul style="list-style-type: none"> <li>Report whether dimensions of context were collected for analysis</li> </ul>	3 (9)
Ethical concerns	None	<ul style="list-style-type: none"> <li>Report details of informed consent and ethical clearance</li> </ul>	13 (38)

(Continued)

Table 2. Continued

Topic	STROBE checklist	Proposed item for an equity-focused extension in observational studies	N (%) of resources
Statistical methods	12a. Describe all statistical methods, including those used to control for confounding	<ul style="list-style-type: none"> <li>• If PROGRESS-Plus factors used to control for confounding, describe how they were defined and rationale.<sup>c</sup></li> </ul>	3 (9)
		<ul style="list-style-type: none"> <li>• Report whether contextual factors were used in adjustment for confounding.<sup>c</sup></li> </ul>	1 (3)
	12b. Describe any methods used to examine subgroups and interactions	<ul style="list-style-type: none"> <li>• Report details of additional analyses related to health equity if applicable.<sup>c</sup></li> <li>• Report whether context or systems were explored.</li> </ul>	9 (26) 2 (6)
	12c. Explain how missing data were addressed	<ul style="list-style-type: none"> <li>• Explain whether missing data were related to individual or contextual factors associated with health inequities.</li> </ul>	2 (6)
Results			
Participants	13a. <sup>a</sup> Report numbers of individuals at each stage of study—e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study,	-	
	13b. Give reasons for nonparticipation at each stage	<ul style="list-style-type: none"> <li>• Describe the losses and exclusions of participants across PROGRESS-Plus.</li> <li>• Describe nonresponse/nonparticipation across PROGRESS-Plus.</li> </ul>	5 (15) 2 (6)
	13c. <sup>a</sup> Consider use of a flow diagram	-	
Descriptive data	14a. Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and potential confounders	<ul style="list-style-type: none"> <li>• Present characteristics across relevant PROGRESS-Plus characteristics.</li> </ul>	11 (32)
	14b. Indicate number of participants with missing data for each variable of interest	<ul style="list-style-type: none"> <li>• Describe whether data on PROGRESS-Plus factors are missing (e.g., ethnicity data in some settings have a high level of missingness).</li> </ul>	3 (9)
	14c. <sup>a</sup> Cohort study—Summaries follow-up time (e.g., average and total amount)	-	
Data	15. <sup>a</sup> Cohort study—Report numbers of outcome events or summary measures over time	-	
	Case-control study—Report numbers in each exposure category, or summary measures of exposure		
	Cross-sectional study—Report numbers of outcome events or summary measures		
Main result	16a. Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included	<ul style="list-style-type: none"> <li>• Report if confounders were defined for contextual or PROGRESS-Plus factors that are associated with health inequities</li> <li>• Justify why certain categories of PROGRESS-Plus are not disaggregated for analysis</li> </ul>	2 (6) 2 (6)
	16b. Report category boundaries when continuous variables were categorized	-	
	16c. If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	-	

(Continued)

Table 2. Continued

Topic	STROBE checklist	Proposed item for an equity-focused extension in observational studies	N (%) of resources
Other analysis	17. Report other analyses done (e.g., analyses of subgroups and interactions and sensitivity analyses)	<ul style="list-style-type: none"> <li>Report other analyses to address health equity questions, if the study had objectives related to health equity.<sup>c</sup></li> </ul>	6 (18)
Discussion			
Key results	18. Summaries key results with reference to study objectives	-	
Limitations	19. Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	<ul style="list-style-type: none"> <li>Report any limitations related to assessing effects on health equity.<sup>b,c</sup></li> </ul>	3 (9)
Interpretation	20. Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	<ul style="list-style-type: none"> <li>Consider importance of context in interpretation of health equity.<sup>c</sup></li> </ul>	7 (21)
Generalizability	21. Discuss the generalizability (external validity) of the study results	<ul style="list-style-type: none"> <li>Discuss external validity to populations across relevant PROGRESS-Plus characteristics, considering issues of possible self-selection, healthy volunteer bias, and losses across PROGRESS-Plus</li> </ul>	6 (18)
		<ul style="list-style-type: none"> <li>Consider implications of exclusion of people across PROGRESS as well as differential participation and/or loss to follow-up</li> </ul>	3 (9)
		<ul style="list-style-type: none"> <li>Consider context in discussion of generalizability</li> </ul>	9 (26)
Implications for research <sup>b</sup>	None	<ul style="list-style-type: none"> <li>Provide implications for research, practice, or policy related to health equity where relevant (e.g., types of research needed to address unanswered questions).<sup>b,c</sup></li> </ul>	1 (3)
Other information			
Funding	22. Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based		
Data sharing <sup>b</sup>	None	<ul style="list-style-type: none"> <li>Describe where the raw data across PROGRESS-plus factors could be accessed.<sup>b</sup></li> </ul>	1 (3)

<sup>a</sup> Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

<sup>b</sup> New items suggested based on resources identified in this review.

<sup>c</sup> Some items are more generic for all observational studies, whereas some (with #) maybe more specific to observational studies related to health equity.

Compared to CONSORT-Equity [36] for clinical trials and PRISMA-Equity [35] for systematic reviews, some of our proposed items are shared across different study designs, such as reporting rationale for focus on health equity, sampling methods designed to reach populations across relevant PROGRESS items, and discussing external validity to populations across relevant PROGRESS-Plus characteristics. Some, however, are unique to observational studies, such as “whether the comparator is considered more advantaged or to have less barriers to health opportunities”. Furthermore, some items are not covered by CONSORT-Equity and PRISMA-Equity but may also be relevant for those study designs, such as report the research area (e.g., personnel with unique professional and cultural backgrounds on equity-related issues) and social location (i.e.,

gender, race, etc.) of investigators, describe any process to ensure that the research is reaching the people experiencing health inequity, and report the definitions of health equity–related terms.

This review, along with other studies that are part of the larger STROBE\_Equity project, will be used to inform the development of the Equity extension to the STROBE reporting guideline. We will present and discuss the results with technical committees and circulate the checklist using a global online survey, together with findings from a methodological survey of observational studies [13]. These studies and surveys will be used to reach consensus on a STROBE\_Equity extension. The protocol for the overall project is available on Open Science Framework [38].

#### 4.1. Strengths and limitations

We used the JBI scoping review methodology [50] to map resources on health equity reporting in research from multiple information sources in an attempt to capture guidance produced and used by relevant stakeholders, including from academic journals, journal policies, research ethics boards, publishers, research funding agencies, and interest groups. Another strength is that we used multidisciplinary team and multiple knowledge users with defined roles and governance strategy to engage diverse perspectives in designing and study and analyzing and interpreting the results [41]. One limitation of our approach is that we were not able to review all available guidance from all sources in every setting. Instead, we used the principle of saturation such that no new items were identified. We also used a structured approach by seeking different sources and balancing between sources (i.e., high-income countries and low-income and middle-income countries) as well as across PROGRESS-Plus characteristics [82]. This helped to identify evidence for all PROGRESS-Plus elements and from different countries or settings. Another limitation is that the checklist is currently a draft for consultation, and some of the items need further elaboration, which are expected to be completed as a justification document for the checklist after consensus and global survey [39]. Two examples will be: (1) the item on reporting a contextual factor used in adjustment needs elaboration on that the adjustment may hide important differences that could inform health policy [83] and authors should transparently report on this if conducted and (2) for effort to avoid selection bias, further elaboration could be used to describe whether selection bias is related to outcomes as particular outcomes may be affected by systemic discrimination.

As expected, the included resources varied across publication type, publisher, scope, levels of detail, and format, which posed a challenge for comprehensive and consistent data extraction. To ensure accuracy of the data extraction, we did all the data extraction in duplicate, with at least one reviewer experienced in equity research for more than 3 years. Each pair of reviewers discussed the results periodically and any questions were presented and solved in weekly team meetings. Furthermore, a senior reviewer verified every supporting recommendation for each item and all the results presented were based on agreement among the review authors.

#### 5. Conclusion

Existing resources for reporting health equity in research are fragmented and only two included resources were focused on any PROGRESS-Plus factors in observational studies. However, we found a strong agreement of the candidate items of our draft checklist with the current

research on reporting of health equity. Based on this review, we have supplemented the checklist with an additional 13 items related to use and define health equity terms, describe the role of racism and discrimination, report background and experience of team members, provide information on logic model, describe process used to reach people experiencing health inequity, describe quality of the comparator (e.g., more advantaged or not), describe the validation of measurements across patients with different backgrounds, report limitations and implications relevant to health equity, and state ways to access raw data across PROGRESS-plus factors. This comprehensive, evidence-based set of reporting items will inform the development of the STROBE\_Equity extension.

#### CRedit authorship contribution statement

**Xiaoqin Wang:** Conceptualization, Screened the references and extracted the data, Formal analysis, Writing – original draft, Writing – review & editing, Approved the final draft, Attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. **Omar Dewidar:** Conceptualization, Screened the references and extracted the data, Revised the manuscript, Writing – review & editing, Approved the final draft. **Anita Rizvi:** Conceptualization, Screened the references and extracted the data, Revised the manuscript, Writing – review & editing, Approved the final draft. **Jimmy Huang:** Screened the references and extracted the data, Writing – review & editing, Approved the final draft. **Payaam Desai:** Screened the references and extracted the data, Writing – review & editing, Approved the final draft. **Rebecca Doyle:** Screened the references and extracted the data, Writing – review & editing, Approved the final draft. **Elizabeth Ghogomu:** Screened the references and extracted the data, Revised the manuscript, Writing – review & editing, Approved the final draft. **Tamara Rader:** Literature search, Revised the manuscript, Writing – review & editing, Approved the final draft. **Stuart G. Nicholls:** Revised the manuscript, Writing – review & editing, Approved the final draft. **Alba Antequera:** Revised the manuscript, Writing – review & editing, Approved the final draft. **Alison Krentel:** Writing – review & editing, Approved the final draft. **Beverley Shea:** Revised the manuscript, Writing – review & editing, Approved the final draft. **Billie-Jo Hardy:** Revised the manuscript, Writing – review & editing, Approved the final draft. **Catherine Chamberlain:** Revised the manuscript, Writing – review & editing, Approved the final draft. **Charles S. Wiysonge:** Revised the manuscript, Writing – review & editing, Approved the final draft. **Cindy Feng:** Revised the manuscript, Writing – review & editing, Approved the final draft. **Clara Juando-Prats:** Revised the manuscript, Writing – review & editing,

Approved the final draft. **Daeria O. Lawson:** Revised the manuscript, Writing – review & editing, Approved the final draft. **Ekwaro A. Obuku:** Revised the manuscript, Writing – review & editing, Approved the final draft. **Elizabeth Kristjansson:** Revised the manuscript, Writing – review & editing, Approved the final draft. **Erik von Elm:** Revised the manuscript, Writing – review & editing, Approved the final draft. **Harry Wang:** Revised the manuscript, Writing – review & editing, Approved the final draft. **Holly Ellingwood:** Revised the manuscript, Writing – review & editing, Approved the final draft. **Hugh Sharma Waddington:** Revised the manuscript, Writing – review & editing, Approved the final draft. **Jacqueline Ramke:** Revised the manuscript, Writing – review & editing, Approved the final draft. **Janet Elizabeth Jull:** Revised the manuscript, Writing – review & editing, Approved the final draft. **Janet Hatcher-Roberts:** Revised the manuscript, Writing – review & editing, Approved the final draft. **Janice Tuft:** Revised the manuscript, Writing – review & editing, Approved the final draft. **Julian Little:** Revised the manuscript, Writing – review & editing, Approved the final draft. **Lawrence Mbuagbaw:** Conceptualization, Revised the manuscript, Writing – review & editing, Approved the final draft. **Laura Weeks:** Revised the manuscript, Writing – review & editing, Approved the final draft. **Loveline Lum Niba:** Revised the manuscript, Writing – review & editing, Approved the final draft. **Luis Gabriel Cuervo:** Revised the manuscript, Writing – review & editing, Approved the final draft. **Luke Wolfenden:** Revised the manuscript, Writing – review & editing, Approved the final draft. **Mwenya Kasonde:** Revised the manuscript, Writing – review & editing, Approved the final draft. **Marc T. Avey:** Revised the manuscript, Writing – review & editing, Approved the final draft. **Melissa K. Sharp:** Revised the manuscript, Writing – review & editing, Approved the final draft. **Michael Johnson Mahande:** Screened the references and extracted the data, Revised the manuscript, Writing – review & editing, Approved the final draft. **Miriam Nkangu:** Revised the manuscript, Writing – review & editing, Approved the final draft. **Olivia Magwood:** Revised the manuscript, Writing – review & editing, Approved the final draft. **Peter Craig:** Revised the manuscript, Writing – review & editing, Approved the final draft. **Peter Tugwell:** Revised the manuscript, Writing – review & editing, Approved the final draft. **Sarah Funnell:** Revised the manuscript, Writing – review & editing, Approved the final draft. **S.G. Noorduyn:** Revised the manuscript, Writing – review & editing, Approved the final draft. **Tamara Kredon:** Revised the manuscript, Writing – review & editing, Approved the final draft. **Tanya Horsley:** Revised the manuscript, Writing – review & editing, Approved the final draft. **Taryn Young:** Revised the manuscript, Writing – review & editing, Approved the final draft. **Tomas Pantoja:** Revised the manuscript, Writing – review & editing, Approved the final draft. **Zulfiqar**

**Bhutta:** Revised the manuscript, Writing – review & editing, Approved the final draft. **Andrea Martel:** Revised the manuscript, Writing – review & editing, Approved the final draft. **Vivian A. Welch:** Conceptualization, Revised the manuscript, Writing – review & editing, Approved the final draft.

## Declaration of Competing Interest

Although Luis Gabriel Cuervo is an official of the Pan American Health Organization, the views expressed in this publication are his sole responsibility and do not necessarily represent the decisions or policies of the Pan American Health Organization (PAHO/WHO).

## Acknowledgments

The authors acknowledge their partners and collaborators on the STROBE-Equity team: George Wells (Canada), Kevin Pottie (Canada), Isabel Fortier (Canada), Elie A. Akl (Lebanon), Alassane Dicko (Canada), Damian Francis (the USA), Regina Greer-Smith (the USA), Michelle Kennedy (Australia), Laurenz Langer (South Africa), G.J. Melendez-Torres (the UK), David Moher (Canada), Patrick M. Okwen (Cameroon), Jennifer Petkovic (Canada), Mark Petticrew (the UK), Alison Riddle (Canada), Larissa Shamseer (Canada), Peter Tanuseputro (Canada), Elizabeth Loder (the USA), Howard White (the UK), Lucy Barker (Canada), Matire Harwood (New Zealand), and Ebenezer Owusu-Addo (Ghana).

## Supplementary data

Supplementary data related to this article can be found at <https://doi.org/10.1016/j.jclinepi.2023.06.009>.

## References

- [1] Whitehead M. The concepts and principles of equity and health. *Health Promot Int* 1991;6(3):217–28.
- [2] Baciu A, Negussie Y, Geller A, Weinstein JN, National Academies of Sciences E, Medicine. The state of health disparities in the United States. *Communities in action: Pathways to health equity*. Washington (DC): National Academies Press (US); 2017: The State of Health Disparities in the United States. Available at <https://www.ncbi.nlm.nih.gov/books/NBK425844/>. Accessed July 10, 2023.
- [3] Allin S. Does equity in healthcare use vary across Canadian Provinces? *Health Policy* 2008;3(4):83–99.
- [4] Wang Z, Yang G, Guo Y. Harnessing the opportunity to achieve health equity in China. *Lancet Public Health* 2021;6(12):e867–8.
- [5] Solar O, Irwin A. *Towards a conceptual framework for analysis and action on the social determinants of health*. Geneva: WHO Commission on Social Determinants of Health; 2007.
- [6] Marmot M, Friel S, Bell R, Houweling TA, Taylor S, Health CoSDo. Closing the gap in a generation: health equity through action on the social determinants of health. *Lancet* 2008;372:1661–9.

- [7] Braveman PA, Kumanyika S, Fielding J, LaVeist T, Borrell LN, Manderscheid R, et al. Health disparities and health equity: the issue is justice. *Am J Public Health* 2011;101:S149–55.
- [8] Braveman P, Tarimo E. Social inequalities in health within countries: not only an issue for affluent nations. *Soc Sci Med* 2002;54(11):1621–35.
- [9] Funai EF, Rosenbush EJ, Lee M-J, Del Priore G. Distribution of study designs in four major US journals of obstetrics and gynecology. *Gynecol Obstet Invest* 2001;51(1):8–11.
- [10] Petticrew M, Roberts H. Evidence, hierarchies, and typologies: horses for courses. *J Epidemiol Community Health* 2003;57:527–9.
- [11] Tugwell P, Petticrew M, Kristjansson E, Welch V, Ueffing E, Waters E, et al. Assessing equity in systematic reviews: realising the recommendations of the Commission on Social Determinants of Health. *BMJ* 2010;341:c4739.
- [12] Craig P, Campbell M, Bauman A, Deidda M, Dundas R, Fitzgerald N, et al. Making better use of natural experimental evaluation in population health. *BMJ* 2022;379:e070872.
- [13] Dewidar O, Rader T, Waddington H, Nicholls SG, Little J, Hardy BJ, et al. Reporting of health equity considerations in equity-relevant observational studies: protocol for a systematic assessment [version 1; peer review: awaiting peer review]. *F1000Research* 2022;11:615.
- [14] Booth C, Tannock I. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. *Br J Cancer* 2014;110:551–5.
- [15] Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, Initiative S. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Ann Intern Med* 2007;147:573–7.
- [16] Waddington HS, Villar PF, Valentine JC. Can non-randomised studies of interventions provide unbiased effect estimates? A systematic review of internal replication studies. *Eval Rev* 2022. 193841x221116721.
- [17] Antequera A, Lawson DO, Noorduyn SG, Dewidar O, Avey M, Bhutta ZA, et al. Improving social justice in covid-19 health research: interim guidelines for reporting health equity in observational studies. *Int J Environ Res Publ Health* 2021;18(17):9357.
- [18] Paremoer L, Nandi S, Serag H, Baum F. Covid-19 pandemic and the social determinants of health. *BMJ* 2021;372:n129.
- [19] Upshaw TL, Brown C, Smith R, Perri M, Ziegler C, Pinto AD. Social determinants of COVID-19 incidence and outcomes: a rapid review. *PLoS One* 2021;16:e0248336.
- [20] Guidance for implementing non pharmacological public health measures in populations in situations of vulnerability in the context of COVID-19. Pan American Health Organization; 2020. Available at <https://iris.paho.org/handle/10665.2/53078>. Accessed July 10, 2023.
- [21] Glover RE, van Schalkwyk MC, Akl EA, Kristjansson E, Lotfi T, Petkovic J, et al. A framework for identifying and mitigating the equity harms of COVID-19 policy interventions. *J Clin Epidemiol* 2020;128:35–48.
- [22] Tenforde MW, Fisher KA, Patel MM. Identifying COVID-19 risk through observational studies to inform control measures. *JAMA* 2021;325:1464–5.
- [23] Faraoni D, Schaefer ST. Randomized controlled trials vs. observational studies: why not just live together? *BMC Anesthesiol* 2016;16(1):102.
- [24] Zachariah R, Rust S, Thekkur P, Khogali M, Kumar AM, Davtyan K, et al. Quality, equity and utility of observational studies during 10 Years of implementing the structured operational research and training initiative in 72 countries. *Trop Med Infect Dis* 2020;5(4):167.
- [25] Pocock SJ, Collier TJ, Dandreo KJ, de Stavola BL, Goldman MB, Kalish LA, et al. Issues in the reporting of epidemiological studies: a survey of recent practice. *BMJ* 2004;329:883.
- [26] Tooth L, Ware R, Bain C, Purdie DM, Dobson A. Quality of reporting of observational longitudinal research. *Am J Epidemiol* 2005;161:280–8.
- [27] Ziemann S, Paetzolt I, Grüßer L, Coburn M, Rossaint R, Kowark A. Poor reporting quality of observational clinical studies comparing treatments of COVID-19 - a retrospective cross-sectional study. *BMC Med Res Methodol* 2022;22:23.
- [28] Quinn TJ, Burton JK, Carter B, Cooper N, Dwan K, Field R, et al. Following the science? Comparison of methodological and reporting quality of covid-19 and other research from the first wave of the pandemic. *BMC Med* 2021;19(1):46.
- [29] Sharp MK, Bertizzolo L, Rius R, Wager E, Gómez G, Hren D. Using the STROBE statement: survey findings emphasized the role of journals in enforcing reporting guidelines. *J Clin Epidemiol* 2019;116:26–35.
- [30] STROBE statement. Available at [https://scholar.google.ca/scholar?hl=en&as\\_sdt=0%2C5&q=+STROBE+statement&oq=strobe](https://scholar.google.ca/scholar?hl=en&as_sdt=0%2C5&q=+STROBE+statement&oq=strobe). Accessed November 28, 2022.
- [31] Dewidar O, Podinic I, Barbeau V, Patel D, Antequera A, Birnie D, et al. Integrating sex and gender in studies of cardiac resynchronization therapy: a systematic review. *ESC Heart Fail* 2022;9(1):420–7.
- [32] Park H, Dewidar O, Tanjong-Ghohomu E, Welch V. Reporting and analysis of sex and gender in transitions of care for older adults: a methods study. *Univ Ott J Med* 2022;11(2):38–43.
- [33] Jahn I, Börnhorst C, Günther F, Brand T. Examples of sex/gender sensitivity in epidemiological research: results of an evaluation of original articles published in JECH 2006–2014. *Health Res Policy Syst* 2017;15(1):1–10.
- [34] Schwab S, Janiaud P, Dayan M, Amrhein V, Panczak R, Palagi PM, et al. Ten simple rules for good research practice. *PLoS Comput Biol* 2022;18(6):e1010139.
- [35] Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, et al. PRISMA-Equity 2012 extension: reporting guidelines for systematic reviews with a focus on health equity. *PLoS Med* 2012;9(10):e1001333.
- [36] Welch VA, Norheim OF, Jull J, Cookson R, Sommerfelt H, Tugwell P. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. *BMJ* 2017;359:j5085.
- [37] CIHR. Knowledge user Engagement. Available at <https://cihr-irsc.gc.ca/e/49505.html>. Accessed December 9, 2022.
- [38] STROBE-equity reporting guidelines. Available at <https://osf.io/h57se/>. Accessed July 4, 2023.
- [39] Funnell S, Jull J, Mbuagbaw L, Welch V, Dewidar O, Wang X, et al. Improving social justice in observational studies: protocol for the development of a global and Indigenous STROBE-equity reporting guideline. *Int J Equity Health* 2023;22(1):55.
- [40] Aromataris E, Munn Z, editors. Chapter 11: scoping reviews Available at *JBI Manual for Evidence Synthesis*. Available at <https://synthesismanual.jbi.global>. Accessed July 4, 2023.
- [41] Rizvi A, Lawson DO, Young T, Dewidar O, Nicholls S, Akl EA, et al. Guidance relevant to the reporting of health equity in observational research: a scoping review protocol. *BMJ Open* 2022;12(5):e056875.
- [42] Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and Explanation. *Ann Intern Med* 2018;169:467–73.
- [43] Bank TW. Indigenous Peoples Overview: The World Bank 2022. Available at <https://www.worldbank.org/en/topic/indigenouspeoples>. Accessed July 4, 2023.
- [44] O'Neill J, Tabish H, Welch V, Petticrew M, Pottie K, Clarke M, et al. Applying an equity lens to interventions: using PROGRESS ensures consideration of socially stratifying factors to illuminate inequities in health. *J Clin Epidemiol* 2014;67:56–64.
- [45] Bramer WM, de Jonge GB, Rethlefsen ML, Mast F, Kleijnen J. A systematic approach to searching: an efficient and complete method to develop literature searches. *J Med Libr Assoc* 2018;106:531–41.
- [46] Clarivate Journal Citation Reports. Available at <https://jcr.clarivate.com/jcr/browse-journals>. Accessed January 6, 2023.
- [47] Joint commitment for action on inclusion and diversity in publishing. Available at <https://www.rsc.org/new-perspectives/talent/joint>

- commitment-for-action-inclusion-and-diversity-in-publishing/. Accessed January 6, 2023.
- [48] International Compilation of Human Research Standards. 2020 edition. Available at <https://www.hhs.gov/ohrp/sites/default/files/2020-international-compilation-of-human-research-standards.pdf>. Accessed January 6, 2023.
- [49] Viergever RF, Hendriks TC. The 10 largest public and philanthropic funders of health research in the world: what they fund and how they distribute their funds. *Health Res Policy Syst* 2016;14:12.
- [50] Peters MD, Godfrey C, McInerney P, Munn Z, Tricco AC, Khalil H. [Chapter 11]: scoping reviews (2020 version). JBI manual for evidence synthesis. JBI; 2020. Available at <https://jbi-global-wiki.refined.site/space/MANUAL>. Accessed July 9, 2023.
- [51] Carroll C, Booth A, Cooper K. A worked example of "best fit" framework synthesis: a systematic review of views concerning the taking of some potential chemopreventive agents. *BMC Med Res Methodol* 2011;11:1–9.
- [52] Miles MB, Huberman AM, Saldaña J. *Qualitative data analysis: A methods sourcebook*. Sage publications; 2018. Available at <https://us.sagepub.com/en-us/nam/qualitative-data-analysis/book246128>. Accessed July 9, 2023.
- [53] Welch VA, Akl EA, Guyatt G, Pottie K, Eslava-Schmalbach J, Ansari MT, et al. GRADE equity guidelines 1: considering health equity in GRADE guideline development: introduction and rationale. *J Clin Epidemiol* 2017;90:59–67.
- [54] Akl EA, Welch V, Pottie K, Eslava-Schmalbach J, Darzi A, Sola I, et al. GRADE equity guidelines 2: considering health equity in GRADE guideline development: equity extension of the guideline development checklist. *J Clin Epidemiol* 2017;90:68–75.
- [55] Welch VA, Akl EA, Pottie K, Ansari MT, Briel M, Christensen R, et al. GRADE equity guidelines 3: considering health equity in GRADE guideline development: rating the certainty of synthesized evidence. *J Clin Epidemiol* 2017;90:76–83.
- [56] Pottie K, Welch V, Morton R, Akl EA, Eslava-Schmalbach JH, Katikireddi V, et al. GRADE equity guidelines 4: considering health equity in GRADE guideline development: evidence to decision process. *J Clin Epidemiol* 2017;90:84–91.
- [57] Pyett P, Waples-Crowe P, van der Sterren A. Engaging with Aboriginal communities in an urban context: some practical suggestions for public health researchers. *Aust N Z J Public Health* 2009;33(1):51–4.
- [58] Azzopardi P, Blow N, Purcell T, Brown N, Ritchie T, Brown A. Investing in the health of Aboriginal and Torres Strait Islander adolescents: a foundation for achieving health equity. *Med J Aust* 2020;212:202–204.e1.
- [59] Huria T, Palmer SC, Pitama S, Beckert L, Lacey C, Ewen S, et al. Consolidated criteria for strengthening reporting of health research involving indigenous peoples: the CONSIDER statement. *BMC Med Res Methodol* 2019;19:173.
- [60] Bartlett JG, Iwasaki Y, Gottlieb B, Hall D, Mannell R. Framework for Aboriginal-guided decolonizing research involving Métis and First Nations persons with diabetes. *Soc Sci Med* 2007;65:2371–82.
- [61] Tordoff DM, Minalga B, Gross BB, Martin A, Caracciolo B, Barbee LA, et al. Erasure and health equity implications of using binary male/female categories in sexual health research and Human immunodeficiency Virus/sexually transmitted infection surveillance: recommendations for transgender-inclusive data collection and reporting. *Sex Transm Dis* 2022;49(2):e45–9.
- [62] Adams N, Pearce R, Veale J, Radix A, Castro D, Sarkar A, et al. Guidance and ethical considerations for undertaking transgender health research and institutional review boards adjudicating this research. *Transgend Health* 2017;2(1):165–75.
- [63] CPATH ethical guidelines for research involving transgender people & communities. Available at <https://cpath.ca/wp-content/uploads/2019/08/CPATH-Ethical-Guidelines-EN.pdf>. Accessed August 8, 2020.
- [64] Matsuda Y, Brooks JL, Beeber LS. Guidelines for research recruitment of underserved populations (EERC). *Appl Nurs Res* 2016;32:164–70.
- [65] Matsumoto M, Bowman R, Worley P. A guide to reporting studies in rural and remote health. *Rural Rem Health* 2012;12:2312.
- [66] Robinson A, Burley M, McGrail MR, Drysdale M, Jones R, Rickard CM. The conducting and reporting of rural health research: rurality and rural population issues. *Rural Rem Health* 2005;5(4):427.
- [67] Global code of conduct for research in resource-poor settings. Available at <https://www.globalcodeofconduct.org/>. Accessed August 8, 2022.
- [68] National Institutes of Health. Amendment: NIH policy and guidelines on the inclusion of women and minorities as subjects in clinical research. Available at 2017. <https://grants.nih.gov/grants/guide/notice-files/NOT-OD-18-014.html>. Accessed August 8, 2022.
- [69] Melby MK, Sievert LL, Anderson D, Obermeyer CM. Overview of methods used in cross-cultural comparisons of menopausal symptoms and their determinants: guidelines for Strengthening the Reporting of Menopause and Aging (STROMA) studies. *Maturitas* 2011;70(2):99–109.
- [70] Bastos JL, Constante HM, Celeste RK, Haag DG, Jamieson LM. Advancing racial equity in oral health (research): more of the same is not enough. *Eur J Oral Sci* 2020;128(6):459–66.
- [71] Lewis-Fernandez R, Raggio GA, Gorritz M, Duan N, Marcus S, Cabassa LJ, et al. GAP-REACH: a checklist to assess comprehensive reporting of race, ethnicity, and culture in psychiatric publications. *J Nerv Ment Dis* 2013;201:860–71.
- [72] Witham MD, Anderson E, Carroll CB, Dark PM, Down K, Hall AS, et al. Ensuring that COVID-19 research is inclusive: guidance from the NIHR INCLUDE project. *BMJ Open* 2020;10(11):e043634.
- [73] Leslie K, Kasza J. Sex and gender inclusion, analysis, and reporting in anaesthesia research. *Br J Anaesth* 2020;124:e43–9.
- [74] Leopold SS, Beadling L, Dobbs MB, Gebhardt MC, Lotke PA, Manner PA, et al. Fairness to all: gender and sex in scientific reporting. *Clin Orthop Relat Res* 2014;472(2):391–2.
- [75] American Journal of Preventive Medicine: Author Instructions. Available at <https://www.elsevier.com/journals/american-journal-of-preventive-medicine/0749-3797/guide-for-authors>. Accessed August 8, 2022.
- [76] Heidari S, Babor TF, De Castro P, Tort S, Curno M. Sex and Gender Equity in Research: rationale for the SAGER guidelines and recommended use. *Res Integr Peer Rev* 2016;1:2.
- [77] Tordoff DM, Minalga B, Gross BB, Martin A, Caracciolo B, Barbee LA, et al. Erasure and health equity implications of using binary male/female categories in sexual health research and Human Immunodeficiency Virus/Sexually Transmitted Infection surveillance: recommendations for transgender-inclusive data collection and reporting. *Sex Transm Dis* 2022;49:e45–9.
- [78] Institute of Medicine Board on Population H, Public Health P. The National academies collection: reports funded by National Institutes of health. In: *Sex-Specific Reporting of Scientific Research: A Workshop Summary*. edn. Washington (DC): National Academies Press (US) Copyright © 2012, National Academy of Sciences.; 2012.
- [79] Mir G, Salway S, Kai J, Karlsen S, Bhopal R, Ellison GT, et al. Principles for research on ethnicity and health: the Leeds Consensus Statement. *Eur J Public Health* 2013;23:504–10.
- [80] Burlew AK, Peteet BJ, McCuistian C, Miller-Roenigk BD. Best practices for researching diverse groups. *Am J Orthopsychiatry* 2019;89:354–68.
- [81] Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. *Int J Qual Health Care* 2007;19:349–57.
- [82] PROGRESS-Plus. <https://methods.cochrane.org/equity/projects/evidence-equity/progress-plus>. Accessed January 6, 2023.
- [83] Kaufman JS. Statistics, adjusted statistics, and maladjusted statistics. *Am J Law Med* 2017;43(2–3):193–208.